| 生物活性 |
Rotundic acid is an orally active triterpenoid with a Kd value of 51.3 µM for PTP1B that downregulates the AKT/mTOR pro-survival pathway and regulates the MAPK pathway, induces S-phase cell cycle arrest, DNA damage, and apoptosis, inhibits cancer cell migration, invasion, angiogenesis, and proliferation, and simultaneously enhances leptin sensitivity, modulates gut microbiota, and reduces cellular senescence, making it applicable to research on hepatocellular carcinoma, obesity, aging, acute lung injury, and type 2 diabetes. |
体外研究 (In Vitro) |
Rotundic acid (10-30 μM) 可剂量依赖性地抑制 HUVEC 细胞的迁移。 Rotundic acid (0-1000 μM) 是人源 PTP1B 的非竞争性抑制剂,其最佳抑制作用依赖于该蛋白的 C 端,对 PTP1B1-298、PTP1B1-321 和 PTP1B1-393 的 IC50 值分别为 2 mM、481.8 μM 和 443.7 μM。 Rotundic acid (3.125-100 μM; 48 h) 可显著延长 BY4741 酵母细胞的复制寿命,在 12.5 μM 浓度下最大延长幅度达 135%。 Rotundic acid (5-20 μM; 24 h) 可降低衰老 WI-38 人胚肺成纤维细胞的细胞衰老水平,表现为 SA-β-gal 阳性细胞减少;同时在 12.5 μM 浓度下可促进细胞增殖。 Rotundic acid (15-60 μM; 24 h) 对 RAW264.7 小鼠巨噬细胞无细胞毒性,在孵育 24 h 后,其浓度最高可达 60 μM。 Rotundic acid (15-60 μM; 1 h pretreatmen) 可呈剂量依赖性降低 LPS (MS-X54539) 刺激的 RAW264.7 小鼠巨噬细胞中亚硝酸盐的生成。 Rotundic acid (15-60 μM; 1 h pretreatment) 可抑制 LPS 诱导 RAW264.7 小鼠巨噬细胞中 TNF-α 和 IL-6 的释放。 Rotundic acid (15-60 μM; 1 h pretreatment) 可调控 LPS 刺激的 RAW264.7 小鼠巨噬细胞中的多条炎症信号通路,包括抑制 NF-κB、MAPK 及 PI3K/Akt/mTOR 的激活、上调 Keap-1/Nrf2/HO-1 信号通路并降低 TLR4 的表达。 Rotundic acid (15-60 μM; 1 h pretreatment) 可降低 LPS 诱导 RAW264.7 小鼠巨噬细胞的 NO 释放量、ROS 生成量及细胞内 Ca2+ 水平。 Rotundic acid 对 Daoy、Hep-2 和 MCF-7 人肿瘤细胞系具有显著的细胞毒活性。
Cell Viability Assay
| Cell Line: |
RAW264.7 murine macrophages |
| Concentration: |
15, 30, 60 μM |
| Incubation Time: |
24 h |
| Result: |
Showed no cytotoxic effect on RAW264.7 macrophages at all tested concentrations, with cell viability remaining above 80% relative to the control group. |
ELISA Assay
| Cell Line: |
LPS-stimulated RAW264.7 murine macrophages |
| Concentration: |
15-60 μM |
| Incubation Time: |
1 h pretreatment, followed by 18 h LPS stimulation |
| Result: |
Significantly decreased the release of TNF-α and IL-6 at all tested concentrations, with consistent, significant inhibition across doses. Increased TNF-α and IL-6 release strongly when LPS was applied alone. |
|
体内研究 (In Vivo) |
Rotundic acid (50 mg/kg;腹腔注射;每 2 天 1 次;持续 60 天) 在人肝癌 HepG2 细胞异种移植 Balb/c 裸鼠模型中实现了 75.6%的肿瘤生长抑制率,同时还可降低肿瘤重量、抑制增殖与血管生成并诱导细胞凋亡,且不会导致显著的体重下降。 Rotundic acid (40 mg/kg;腹腔注射;每月 1 周;持续 6 个月) 可使自然衰老的雄性 C57BL/6J 小鼠的平均寿命延长 16.2%,并改善其衰老相关功能指标。 Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 可使高脂饮食诱导的肥胖小鼠体重最高降低 26.3%,并呈剂量依赖性减少其食物摄入量。 Rotundic acid (腹腔注射;40 mg/kg;每日 1 次;连续 14 天) 可使平均体重约为 58 g 的高脂饮食诱导肥胖小鼠的体重降低 25.1%,同时减少其食物摄入量、降低脂肪组织重量并下调血浆瘦素水平。 Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 对正常瘦型雄性 C57BL/6N 小鼠的体重、食物摄入量或脂肪组织质量均无影响。 Rotundic acid (40 mg/kg;腹腔注射;每日一次;连续 14 天) 可改善高脂饮食诱导肥胖小鼠的葡萄糖稳态与胰岛素敏感性。 Rotundic acid (20-40 mg/kg;腹腔注射) 可使二甲苯诱导的小鼠耳肿胀减轻 80%以上,并改善相关的病理性组织损伤。 Rotundic acid (20-40 mg/kg;腹腔注射) 可将 LPS 诱导的内毒素休克小鼠的 144 小时存活率提升至 30%。 Rotundic acid (10-40 mg/kg;腹腔注射) 可降低 LPS 诱导的炎症标志物水平,改善肺功能损伤,并缓解小鼠急性肺损伤模型中的肺部病理性损伤。 Rotundic acid (40 mg/kg;灌胃;每日;8 周) 可改善 2 型糖尿病大鼠的糖脂代谢、降低血压、保护其免受心血管及肝肾损伤、减轻氧化应激与炎症反应,并恢复由高脂饮食联合低剂量链脲佐菌素诱导的肠道菌群失调。
| Animal Model: |
Balb/c nude (male, 5 weeks old, subcutaneous HepG2 cell xenograft) |
| Dosage: |
50 mg/kg |
| Administration: |
i.p.; every 2 days; 60 days |
| Result: |
Reduced mean tumor volume to 78.95 mm3 (vs. 323.64 mm3 in controls), achieving 75.6% tumor growth inhibition. Reduced tumor weights significantly compared to controls. Showed no significant body weight loss. Reduced expression of proliferation marker Ki-67, angiogenesis marker CD-31, phosphorylated AKT, and phosphorylated mTOR in tumor tissue. Increased expression of phosphorylated p38 MAPK in tumor tissue. Induced apoptosis via increased cleaved PARP and cleaved caspase-3 in tumor tissue. |
| Animal Model: |
C57BL/6N (male, 8 weeks old, high-fat diet-induced obese) |
| Dosage: |
40 mg/kg |
| Administration: |
i.p.; daily; 14 days |
| Result: |
Reduced body weight in a dose-dependent manner, with the 40 mg/kg dose causing a 26.3% decrease. Reduced daily food intake by 62.3% in the first week of 40 mg/kg treatment. |
| Animal Model: |
BALB/c (male, 18-20 g, LPS-induced acute lung injury model) |
| Dosage: |
10 mg/kg; 20 mg/kg; 40 mg/kg |
| Administration: |
i.p.; two doses: 2 hours before LPS, 4 hours after LPS |
| Result: |
Decreased LPS-induced increases in blood lymphocytes, neutrophils, and white blood cells. Reduced levels of TNF-α, IL-6, and IL-1β in serum, bronchoalveolar lavage fluid, and lung tissue homogenate. Reduced myeloperoxidase activity in lung tissue. Significantly recovered mouse lung function including peak expiratory flow, dynamic lung compliance, inspiratory resistance, expiratory resistance, and minute ventilation volume. Ameliorated LPS-induced alveolar interstitial exudation, alveolar structural destruction, and inflammatory cell infiltration observed via H&E staining. |
| Animal Model: |
Sprague-Dawley (5-week-old male, weight 180-220 g, type 2 diabetes induced by high-fat diet + low-dose streptozotocin) |
| Dosage: |
40 mg/kg |
| Administration: |
i.g.; daily; 8 weeks |
| Result: |
Increased body weight compared to T2D model rats. Decreased water intake and increased food intake compared to T2D model rats. Reduced fasting glucose, glycated hemoglobin A1c (HbA1c), and insulin levels compared to T2D model rats. Reduced glucose area under the curve (AUC) for OGTT and ITT, and reduced HOMA-IR index compared to T2D model rats. Significantly reduced serum total glyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and free fatty acid (FFA) levels, and increased high-density lipoprotein cholesterol (HDL-C) levels compared to T2D model rats. Reduced systolic blood pressure (SYS), diastolic blood pressure (DIA), mean arterial pressure (MAP), and serum angiotensin-2 (ANG-2) levels compared to T2D model rats. Significantly reduced serum myocardial enzymes (α-HBDH: 151.9 U/L, CK: 0.418 U/L, CK-MB: 191.7 U/L, LDH: 1854.0 U/L), C-reactive protein (CRP: 422.7 pg/mL), endothelin-1 (ET-1: 48.9 pg/mL), alanine aminotransferase (ALT: 44.6 IU/L), aspartate aminotransferase (AST: 99.32 IU/L), alkaline phosphatase (ALP: 15.1 KU/100 mL), uric acid (UA: 131.0 μmol/L), and urea nitrogen (BUN: 5.3 mmol/L) compared to T2D model rats. Increased serum superoxide dismutase (SOD: 246.7 U/L) and interleukin-4 (IL-4: 55.2 pg/mL) levels compared to T2D model rats. Decreased serum malondialdehyde (MDA: 4.73 nmol/mL), tumor necrosis factor-α (TNF-α: 259.1 pg/mL), interferon-γ (INF-γ: 16.6 pg/mL), interleukin-1β (IL-1β: 11.0 pg/mL), and interleukin-6 (IL-6: 8.7 pg/mL) levels compared to T2D model rats. Increased Chao1 and Shannon α-diversity indices compared to T2D model rats. Reversed the elevated Firmicutes-to-Bacteroidetes ratio seen in T2D model rats. Increased relative abundances of beneficial/commensal genera Prevotella, Ruminococcus, Leuconostoc, and Streptococcus compared to T2D model rats. Decreased relative abundances of opportunistic pathogen genera Klebsiella and Proteus compared to T2D model rats. |
|